Published in Hepatitis Weekly, October 24th, 2005
"Few clinical trials have investigated the use of lamivudine (LAM) in patients with decompensated cirrhosis related to chronic hepatitis B. The aim of the present study was to evaluate the efficacy of extended LAM treatment and to determine the timing of LAM administration in patients with decompensated cirrhosis. A total of 17 patients were treated with LAM 100 mg/day," scientists in South Korea report.
"The mean duration of follow up was 28±8.4 months (range: 14-42 months). All patients were evaluated for evidence of clinical, biochemical and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.